Bode C - Search Results

1

Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: a subgroup analysis from the GUSTO V and FASTER trials.

Bertram U, Moser M, Peter K, Kuecherer HF, Bekeredjian R, Straub A, Nordt TK, Bode C, Ruef J. Bertram U, et al. Among authors: bode c. J Thromb Thrombolysis. 2002 Dec;14(3):197-203. doi: 10.1023/a:1025044625487. J Thromb Thrombolysis. 2002. PMID: 12913399

2

The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, alphaMbeta2).

Schwarz M, Nordt T, Bode C, Peter K. Schwarz M, et al. Among authors: bode c. Thromb Res. 2002 Aug 15;107(3-4):121-8. doi: 10.1016/s0049-3848(02)00207-4. Thromb Res. 2002. PMID: 12431477

3

Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates.

Moser M, Bertram U, Peter K, Bode C, Ruef J. Moser M, et al. Among authors: bode c. J Cardiovasc Pharmacol. 2003 Apr;41(4):586-92. doi: 10.1097/00005344-200304000-00011. J Cardiovasc Pharmacol. 2003. PMID: 12658060

4

Independence of growth factor induced plasminogen activator inhibitor type-1 (PAI-1) expression from the 4G/5G polymorphism of the PAI-1 gene.

Nordt TK, Eschenfelder E, Peter K, Sobel BE, Bode C. Nordt TK, et al. Among authors: bode c. Thromb Haemost. 2003 Jul;90(1):36-42. Thromb Haemost. 2003. PMID: 12876623

5

Adhesion of monocytes to medical steel as used for vascular stents is mediated by the integrin receptor Mac-1 (CD11b/CD18; alphaM beta2) and can be inhibited by semiconductor coating.

Schuler P, Assefa D, Ylänne J, Basler N, Olschewski M, Ahrens I, Nordt T, Bode C, Peter K. Schuler P, et al. Among authors: bode c. Cell Commun Adhes. 2003 Jan-Feb;10(1):17-26. doi: 10.1080/15419060302065. Cell Commun Adhes. 2003. PMID: 12881037 Free article.

6

Construction and in vitro testing of a novel fab-hirudin-based fusion protein that targets fibrin and inhibits thrombin in a factor xa-dependent manner.

Peter K, Gupta A, Nordt T, Bauer S, Runge MS, Bode C. Peter K, et al. Among authors: bode c. J Cardiovasc Pharmacol. 2003 Aug;42(2):237-44. doi: 10.1097/00005344-200308000-00013. J Cardiovasc Pharmacol. 2003. PMID: 12883328

7

Reversibility versus persistence of GPIIb/IIIa blocker-induced conformational change of GPIIb/IIIa (alphaIIbbeta3, CD41/CD61).

Schwarz M, Katagiri Y, Kotani M, Bassler N, Loeffler C, Bode C, Peter K. Schwarz M, et al. Among authors: bode c. J Pharmacol Exp Ther. 2004 Mar;308(3):1002-11. doi: 10.1124/jpet.103.058883. Epub 2003 Nov 14. J Pharmacol Exp Ther. 2004. PMID: 14617694

8

Use of GPIIb/IIIa inhibitors in cardiovascular medicine.

Ahrens I, Peter K, Bode C. Ahrens I, et al. Among authors: bode c. Expert Rev Cardiovasc Ther. 2003 Jul;1(2):233-42. doi: 10.1586/14779072.1.2.233. Expert Rev Cardiovasc Ther. 2003. PMID: 15030283 Review.

9

Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones.

Zirlik A, Leugers A, Lohrmann J, Ernst S, Sobel BE, Bode C, Nordt TK. Zirlik A, et al. Among authors: bode c. Thromb Haemost. 2004 Apr;91(4):674-82. doi: 10.1160/TH03-06-0384. Thromb Haemost. 2004. PMID: 15045127

10

Fibrin-targeted direct factor Xa inhibition: construction and characterization of a recombinant factor Xa inhibitor composed of an anti-fibrin single-chain antibody and tick anticoagulant peptide.

Hagemeyer CE, Tomic I, Jaminet P, Weirich U, Bassler N, Schwarz M, Runge MS, Bode C, Peter K. Hagemeyer CE, et al. Among authors: bode c. Thromb Haemost. 2004 Jul;92(1):47-53. doi: 10.1160/TH04-01-0047. Thromb Haemost. 2004. PMID: 15213844

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,402 results

Search Page

Filters